BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
All that You Really want to Be aware of Dental Inserts Facilities - 2Most loved Occasion Dish: What Makes Your Merry Table?
- 3Step by step instructions to Protect Your Speculations with Cd Rates
- 4'Zootopia 2' movie reviews: A heartwarming, hysterical and earnest 'ode to community'
- 5Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- Figure out How to Remain Persuaded During Your Internet based Degree Program
- Explainer-What will change with the US reclassification of marijuana?
- When faith comes under fire: How Iran’s repression of religious minorities has increased
- Is Chinese food truly flavorful?
- German petrol stations hike prices as once-a-day rule takes effect
- The newest 'Project Hail Mary' trailer shows Ryan Gosling befriending an alien in Phil Lord and Chris Miller's space epic
- Over 250,000 cases of shredded cheese recalled over possible metal fragments
- We may have one thing in common with jellyfish, new research finds
- Explora Journeys becomes latest cruise line to be impacted by Middle East war
